Germany: How the GKV-FinStG law is transforming the pharma P&R landscape

Published on April 5, 2023

In November 2022, the new GKV Financial Stabilization Act (GKV-FinStG) came into effect after being passed by the German parliament. The objective of the law is to financially stabilize German statutory health insurance policies (GKV). To achieve this objective, far-reaching changes in the legal framework for pricing and reimbursement of innovative pharmaceuticals have been adopted.

Our industry experts Gabor Kiss, Christoph Engelke, and Alexandra Gottswinter have investigated the legislative changes and analyzed the implications of the GKV-FinStG for pricing and reimbursement of innovative drugs in Germany. In this report, they provide an overview of the most important changes to the AMNOG process and discuss remaining uncertainties. Furthermore, they provide an overview of strategic implications that may arise for pharmaceutical companies when planning and managing pricing and reimbursement.

…

Germany

Continue reading on website
Other news

UK: Integrated Care Systems – lessons and outlook from the first six months

April 5, 2023
In July 2022, Integrated Care Systems (ICSs) became the statutory bodies responsible for commissioning medicines and budget allocation, replacing Clinical Commissioning Groups (CCGs). In this article, we review the key budget- and funding-related challenges, the outlook for 2023, and implications for therapies preparing to launch in the UK.UK financial environmentThe current UK healthcare environm

China: Commercial health insurance trends

April 5, 2023
While the National Reimbursement Drug List (NRDL) continues to be the dominant path to public reimbursement in China, commercial health insurance (CHI) in China is quickly emerging as an alternative reimbursement option. Its development gained momentum particularly around 2015, driven by government policy support, unmet demand, and supply-side innovations.City CHI has been one of the fastest-growi